

Table S1. Antimicrobial susceptibility profile of *P. aeruginosa* clinical isolates used in this study

| Stock # | PTZ | A/C | AZT | CFZ | CTR | CPM | CAZ | IMI | MER | DOR | ETP | TOB | GEN | AMK | TGC | DOX | CST | SXT |
|-----------------------|-----|-----|-----|------|-----|-----|-----|-----|-----|-----|-----|------|------|-----|-----|-----|------|-----|
| 100036 | 8 | >32 | 8 | >128 | 32 | 4 | 8 | 8 | 4 | 4 | >32 | 64 | >32 | 32 | >16 | >32 | 2 | >8 |
| 101885 ⁽¹⁾ | 16 | >32 | 32 | >128 | 32 | 8 | 8 | 1 | 1 | 0.5 | 32 | ≤0.5 | ≤0.5 | ≤1 | 8 | >32 | 1 | >8 |
| PA259-96918 | 64 | >32 | 16 | >128 | >64 | >64 | >32 | 32 | >32 | >32 | >32 | >64 | >32 | >64 | 8 | 16 | 1 | >8 |
| PA260-97103 | 128 | >32 | 16 | >128 | >64 | 16 | 32 | 32 | 16 | 16 | >32 | 32 | >32 | 4 | 16 | 16 | 1 | 2 |
| PA262-101856 | 64 | >32 | 32 | >128 | 64 | 32 | 16 | 32 | 32 | 8 | >32 | >64 | >32 | >64 | >16 | >32 | 1 | >8 |
| PA264-104354 | 256 | >32 | 64 | >128 | >64 | 32 | >32 | 32 | >32 | 16 | >32 | 64 | >32 | 8 | >16 | >32 | 1 | >8 |
| 91433 | 64 | >32 | ND | >128 | >64 | 16 | >32 | 32 | 8 | 8 | >32 | 8 | 32 | >32 | >16 | 32 | 4 | 1 |
| 101243 | 128 | >32 | ND | >128 | >64 | 64 | >32 | 16 | 16 | 16 | >32 | ≥64 | >32 | >64 | 8 | 4 | 1024 | 4 |

PTZ: piperacillin-tazobactam; A/C: amoxicillin-clavulanic acid; AZT: aztreonam; CFZ: cefazolin; CTR: ceftriaxone; CPM: ceftazidime; CAZ: imipenem; MER: meropenem; DOR: doripenem; ETP: ertapenem; TOB: tobramycin; GEN: gentamicin; AMK: amikacin; TGC: tigecycline; DOX: doxycycline; CST: colistin; SXT: trimethoprim-sulfamethoxazole; ND: not determined; ⁽¹⁾ non MDR/XDR strain